Molecularly targeted Therapy: Have the floodgates opened?

[1] Chabner BA, 2001, ONCOLOGIST, V6, P230

[2] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042

[4] Druker BJ, 2001, LANCET, pS11

[5] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 3 - 7

[6] FRANKEL, 2004, WASHINGTON POST 0502, pD1

[7] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246

[8] PDGFRA activating mutations in gastrointestinal stromal tumors [J]. SCIENCE, 2003, 299 (5607) : 708 - 710

[9] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4342 - 4349

[10] Kaelin William G Jr, 2004, Sci STKE, V2004, ppe12, DOI 10.1126/stke.2252004pe12

[1] Chabner BA, 2001, ONCOLOGIST, V6, P230

[2] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042

[4] Druker BJ, 2001, LANCET, pS11

[5] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 3 - 7

[6] FRANKEL, 2004, WASHINGTON POST 0502, pD1

[7] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246

[8] PDGFRA activating mutations in gastrointestinal stromal tumors [J]. SCIENCE, 2003, 299 (5607) : 708 - 710

[9] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4342 - 4349

[10] Kaelin William G Jr, 2004, Sci STKE, V2004, ppe12, DOI 10.1126/stke.2252004pe12